Investor Backing & Capital Strength:
A $372M Series D in June 2024 led by a16z with Sanofi participation provides substantial capital to expand the pipeline and AI capabilities. Reports characterize this as a material valuation step-up and part of a sizable overall funding base.
Strategic Partnerships:
A first-of-its-kind AI collaboration with Sanofi and OpenAI and an out‑licensing deal of gusacitinib to Sanofi (up to €545M) indicate strong external validation and access to enterprise-scale deployment. These alliances reinforce market credibility while opening channels for co-development and monetization.
Product Line Growth:
Ongoing in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor and an anti‑CD226 program) and 2026 updates showing rapid Phase 1 initiation suggest a broadening and advancing portfolio. The rebrand and model shift aim to support a faster-moving, diversified pipeline across immunology and related areas.
